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Editorial on the Research Topic
Metformin: Beyond Diabetes
Metformin, a member of the family of biguanides, is one of the most prescribed medications in the
US and Europe and remains the first-line treatment for type 2 Diabetes (T2D) worldwide. It is a
low cost medication, relatively well-tolerated, that has been given to millions of patients for more
than 60 years in Europe. The literature on metformin is immense and recent discoveries in basic
research place metformin on the short-list of the most promising drug for repurposing. Pioneering
mechanistic studies demonstrating thatmetformin inhibits complex I in the respiratory chain of the
mitochondria (1, 2) and the work of Zhou et al. showing that metformin activates AMP-activated
protein kinase (AMPK) by inducing its phosphorylation at Thr172 (3), opened new horizons
for maximizing clinical exploitation of metformin. Not only did they spur better understanding
of metformin’s action in T2D (4–6), but they also provided rational bases for laboratories to
study the therapeutic potential of metformin outside of the conventional management of T2D.
Twenty years on however, there still remains much debate regarding the key molecular target(s) of
metformin. In this Research Topic, the evidence regarding direct effects of metformin on complex I
of the electron transport chain and mitochondria are discussed in two focussed reviews (Fontaine;
Vial et al.). They address topical research alongside earlier studies on the mechanism of action
of metformin on mitochondrial complex I, how metformin modulates reactive oxygen species
(ROS) production to prevent mitochondrial-mediated apoptosis and how the drug protects against
permeability transition pore (PTP)-induced cell death. These effects are discussed in the context of
T2D and cancer.
Metformin is now a well-established disruptor of cellular energy supply that targets the
mitochondria [(7); Fontaine; Vial et al.]. The resulting compensatory changes on cellular
metabolism to provide alternative sources of ATP and metabolites are detailed in this Research
Topic by Andrzejewski et al.: including increased glycolysis, modifications of glutamine
metabolism, and increase in PGC-1α [amajor regulator ofmitochondrial biogenesis also implicated
in cancer (8)]. These adaptations are thought to play a central role in the resistance to metformin
in cancer cells.
Activation of AMPK has been reported to inhibit the mechanistic target of rapamycin complex
1 (mTORC1) signaling pathway frequently activated in cancer cells (9). Furthermore, the tumor
suppressor LKB1 was demonstrated to phosphorylate AMPK in response to biguanides (10). What
then are the consequences in terms of cancer incidence in patients treated with metformin for
decades? Observational evidence suggests that metformin reduces the incidence of cancer in people
with diabetes (11). In this Research Topic three articles focus on the action of metformin on cancer
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andmore specifically onmelanoma (Jaune and Rocchi), leukemia
(Biondani and Peyron), and colorectal cancer (Higurashi
and Nakajima). These reviews describe in detail the recent
advances concerning in vivo effects and the different molecular
mechanisms underlying the anti-cancer action of metformin
(AMPK dependent/independent effects, role of p53 and cellular
effects: apoptosis, autophagy, proliferation, and cell migration),
and present ongoing clinical trials for the prevention or treatment
of various types of cancer.
One of the first reported benefits of metformin in reproductive
biology was the increase of fertility in patients with polycystic
ovary syndrome (PCOS) (12). This pathology is often associated
with insulin resistance; thus, it is perhaps not surprising
in hindsight that metformin ameliorates PCOS. Likewise,
metformin has beneficial effects on obese male fertility (13).
This important aspect of metformin action is addressed in a
review that also discusses the potential epigenetic modifications
induced by metformin in this context (Faure et al.). Among
epigenetic modifications, histone acetylation/deacetylation plays
a major role in the regulation of gene expression and
metformin via AMPK was shown to regulate the expression
of Sirtuin1 (Sirt1), a member of the class III (NAD+-
dependent) histone deacetylases (HDACs) (14). An original
research article of this collection by the group of J. Menendez,
uses a computational approach to identify putative sites
of interaction between Sirt1 and metformin (Cuyàs et al.).
This is an important issue since metformin similarly to
Sirtuins has been reported to expand longevity from yeast to
mammals (15).
One of the most surprising effects of metformin found in
recent years is its action on the gut microbiota. Indeed, the
original discoverymade by Oluf Pedersen’s lab demonstrated that
metformin causes a shift in the composition of microbiota altered
during T2D (16). Two examples of the action of metformin
on gut microbiota are given in two original research papers of
the “Metformin: beyond diabetes” Research Topic (Wang et al.;
Ji et al.).
Finally, there is growing evidence showing that metformin
may have therapeutic potential in neurodegenerative disease.
Rotermund et al. contribute a comprehensive review on the topic.
In this article, evidence for effects of metformin on Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclerosis,
and Huntington’s disease are summarized. Metformin has a
protective action on neurons mainly because it protects from
oxidative stress and neuroinflammation through mechanisms
implicating mitochondria and glucose metabolism. Once again,
cellular metabolism is at the forefront.
There are so many pathologies that have been shown to be
impacted by metformin that it is a first-class candidate for drug
repurposing in the near future. Besides cardiovascular disease
(17, 18), tuberculosis (19) and very recently multiple sclerosis
(20) may show promise. Future investigations and large-scale
prospective clinical trials, some of them currently ongoing, will
clarify this fascinating issue.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
Research funded by Fondation ARC to FB, BHF PG/18/79/34106
and the Newton Fund to GR.
REFERENCES
1. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X.
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted
on the respiratory chain complex I. J Biol Chem. (2000) 275:223–8.
doi: 10.1074/jbc.275.1.223
2. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts
its anti-diabetic effects through inhibition of complex 1 of the
mitochondrial respiratory chain. Biochem J. (2000) 348(Pt 3), 607–614.
doi: 10.1042/bj3480607
3. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-
activated protein kinase in mechanism of metformin action. J Clin Invest.
(2001) 108:1167–74. doi: 10.1172/JCI13505
4. ForetzM, Guigas B, Viollet B. Understanding the glucoregulatorymechanisms
of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. (2019) 15:569–
89. doi: 10.1038/s41574-019-0242-2
5. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al.
Metformin inhibits hepatic gluconeogenesis in mice independently of the
LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest.
(2010) 120:2355–69. doi: 10.1172/JCI40671
6. Madiraju AK, Qiu Y, Perry RJ, Rahimi Y, Zhang XM, Zhang D, et al.
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in
vivo. Nat Med. (2018) 24:1384–94. doi: 10.1038/s41591-018-0125-4
7. Bost F, Decoux-Poullot AG, Tanti JF, Clavel S. Energy disruptors: rising stars
in anticancer therapy?Oncogenesis. (2016) 5:e188. doi: 10.1038/oncsis.2015.46
8. Kaminski L, Torrino S, Dufies M, Djabari Z, Haider R, Roustan
FR, et al. PGC1alpha inhibits polyamine synthesis to suppress
prostate cancer aggressiveness. Cancer Res. (2019) 79:3268–80.
doi: 10.1158/0008-5472.CAN-18-2043
9. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism,
and Disease. Cell. (2017) 168:960–76. doi: 10.1016/j.cell.2017.
02.004
10. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al.
Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and
MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase
cascade. J Biol. (2003) 2:28. doi: 10.1186/1475-4924-2-28
11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR,Morris AD.Metformin
and reduced risk of cancer in diabetic patients. BMJ. (2005) 330:1304–5.
doi: 10.1136/bmj.38415.708634.F7
12. Patel R, Shah G. Effect of metformin on clinical, metabolic and endocrine
outcomes in women with polycystic ovary syndrome: a meta-analysis of
randomized controlled trials. Curr Med Res Opin. (2017) 33:1545–57.
doi: 10.1080/03007995.2017.1279597
13. Ferreira C, Sousa M, Rabaca A, Oliveira PF, Alves MG, Sa R. Impact
of metformin on male reproduction. Curr Pharm Des. (2015) 21:3621–33.
doi: 10.2174/1381612821666150710150041
14. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC,
et al. AMPK regulates energy expenditure by modulating NAD+metabolism
and SIRT1 activity. Nature. (2009) 458:1056–60. doi: 10.1038/nature
07813
Frontiers in Endocrinology | www.frontiersin.org 2 December 2019 | Volume 10 | Article 851
Bost et al. Editorial: Metformin: Beyond Diabetes
15. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL,
Scheibye-Knudsen M, et al. Metformin improves healthspan and lifespan in
mice. Nat Commun. (2013) 4:2192. doi: 10.1038/ncomms3192
16. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S,
et al. Disentangling type 2 diabetes and metformin treatment signatures in the
human gut microbiota. Nature. (2015) 528:262–6. doi: 10.1038/nature15766
17. MohanM, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, et al. A
randomized controlled trial of metformin on left ventricular hypertrophy in
patients with coronary artery disease without diabetes: the MET-REMODEL
trial. Eur Heart J. (2019) 40:3409–17. doi: 10.1093/eurheartj/ehz203
18. Rena G, Lang CC. Repurposing metformin for cardiovascular disease.
Circulation. (2018) 137:422–4. doi: 10.1161/CIRCULATIONAHA.117.031735
19. Leung CC. Repurposing metformin to prevent and treat tuberculosis.
Respirology. (2018) 23:974–5. doi: 10.1111/resp.13371
20. Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al.
Metformin restores CNS remyelination capacity by rejuvenating aged stem
cells. Cell Stem Cell. (2019) 25:473–485.e478. doi: 10.1016/j.stem.2019.08.015
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Bost, Rena and Viollet. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 3 December 2019 | Volume 10 | Article 851
